Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer-Reference-Cited by-同舟云学术

Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer

Published:2006 Issue:8 Volume:107 Page:1873-1882
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Yang Chih-Hsin,Shih Jin-Yuan,Chen Kun-Chieh,Yu Chong-Jen,Yang Tsung-Ying,Lin Ching-Pei,Su Wen-Pin,Gow Chien-Hung,Hsu Chiun,Chang Gee-Chen,Yang Pan-Chyr

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference35 articles.

1. Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors

2. Dose-comparative monotherapy trials of ZD1839 in previously treated non–small cell lung cancer patients

3. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

4. Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lung Adenocarcinoma Metastasis to the Vocal Cord;Ear, Nose & Throat Journal;2022-06-20

2. Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost;Journal of the Formosan Medical Association;2020-12

3. Molecular genetic profiling of small cell lung carcinoma in a Chinese cohort;Translational Cancer Research;2019-02

4. Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma;Tuberculosis and Respiratory Diseases;2019

5. Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations;Oncology;2018